Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Raptor begins enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

June 30, 2010

Palatin Technologies claims new melanocortin receptor ligands

June 30, 2010

GSK-1362885 is safe in healthy volunteers and patients with type 2 diabetes

June 30, 2010

Corcept nears enrollment completion in phase III Corlux trial

June 29, 2010

CHMP recommends approval of Shire's VPRIV for type 1 GD

June 29, 2010

Interim phase II data reported on ENB-0040 in childhood hypophosphatasia

June 29, 2010

Pooled phase III data show efficacy of tesamorelin in HIV-related lipodystrophy

June 29, 2010

Sanofi-aventis and Metabolex enter into licensing agreement for novel antidiabetic

June 28, 2010

FDA advisory committee meeting scheduled to review Contrave NDA

June 28, 2010

Versartis commences phase Ia trial of VRS-859 in type 2 diabetes

June 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...